FAM172A Inhibitors
Chemical inhibitors of FAM172A function by targeting various signaling pathways that are crucial for the protein's activity within the cell. Wortmannin and LY294002 are inhibitors that directly target phosphoinositide 3-kinases (PI3Ks), which are upstream regulators of the AKT signaling pathway, a key pathway that influences FAM172A activity. By inhibiting PI3K, these chemicals suppress AKT phosphorylation and activation, leading to a decrease in FAM172A activity. Rapamycin, on the other hand, inhibits the mTOR pathway, which is downstream of PI3K/AKT signaling. Since mTOR is involved in cell growth and survival, the inhibition of this pathway by rapamycin can result in a reduction of cellular processes that involve FAM172A. U0126 and PD98059 are specific inhibitors of MEK1/2, affecting the MAPK/ERK pathway, which is implicated in cell cycle regulation and apoptosis, processes in which FAM172A is involved. Through the inhibition of this pathway, U0126 and PD98059 can lead to decreased FAM172A activity.
Additionally, SP600125 and SB203580 target other components of the MAPK pathway by inhibiting JNK and p38 MAP kinase, respectively. Since FAM172A is connected with cellular stress responses that are regulated by JNK and p38 MAPK, the inhibition by these chemicals can impede the actions mediated by FAM172A related to stress signaling. Furthermore, PP2, Dasatinib, and Imatinib are tyrosine kinase inhibitors that can impact FAM172A activity by affecting various signaling pathways. PP2 specifically inhibits Src family tyrosine kinases, while Dasatinib is a broad-spectrum inhibitor affecting Src kinases among others. Imatinib targets kinases such as BCR-ABL, c-KIT, and PDGFR, which are associated with signaling pathways that intersect with FAM172A's role. Lastly, Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, affecting signaling pathways that lead to FAM172A activation, such as the PI3K/AKT and MAPK/ERK pathways. The collective action of these inhibitors leads to a comprehensive downregulation of FAM172A activity by affecting multiple regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of phosphoinositide 3-kinases (PI3Ks). FAM172A is reported to interact with the PI3K/AKT signaling pathway. By inhibiting PI3K, wortmannin can suppress AKT phosphorylation and activation, which in turn could lead to a reduction in FAM172A activity as its function is influenced by the state of the PI3K/AKT pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of phosphoinositide 3-kinases (PI3Ks), which are upstream regulators of the AKT signaling pathway. Since FAM172A activity is associated with PI3K/AKT signaling, inhibition of PI3K by LY294002 results in decreased AKT activation and consequently can inhibit the downstream effects mediated by FAM172A. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway is downstream of PI3K/AKT signaling and is known to be involved in cell growth and survival. Through the inhibition of mTOR, rapamycin can indirectly diminish the cellular processes in which FAM172A is implicated, as mTOR activity can affect FAM172A function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. This pathway has been implicated in cell cycle regulation and apoptosis, processes in which FAM172A may play a role. By inhibiting MEK, PD98059 can inhibit the MAPK/ERK pathway, potentially leading to decreased FAM172A activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 functions as a selective inhibitor of MEK1 and MEK2, affecting the MAPK/ERK pathway. By inhibiting this pathway, U0126 can impact cellular functions related to FAM172A, potentially leading to an inhibition of FAM172A's functional role in these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK pathway. FAM172A, connected with cellular stress responses, could be influenced by JNK activity. Inhibition of JNK by SP600125 can, therefore, impede the actions mediated by FAM172A that are related to stress response signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, another member of the MAPK pathway. As FAM172A is involved in cellular processes that are potentially regulated by p38 MAPK signaling, the inhibition of this kinase by SB203580 can lead to a decrease in FAM172A activity related to these stress response and inflammatory pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases can influence various signaling pathways, including those that FAM172A may be involved in, such as cell cycle regulation and apoptosis. Inhibition of Src kinases by PP2 can result in a reduction of FAM172A function within these pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, including Src family kinases. By inhibiting these kinases, dasatinib can interfere with signaling pathways affecting cell cycle and survival, potentially leading to a decrease in FAM172A activity in these contexts. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, c-KIT, and PDGFR. As these kinases participate in signaling pathways that can intersect with those involving FAM172A, the inhibition of these kinases by imatinib could result in decreased activity of FAM172A in related cellular functions. | ||||||